|
ISSN: 1040-8401 Print
|
|
|
|
| |
You can order a single issue or an individual article, as well as view the table of contents or article abstract by clicking on the volume number, then the issue number in the right sidebar.
|
|
|
|
|
|
Institutional price: $942.00
|
|
Online subscription
|
|
DOI: 10.1615/CritRevImmunol.v25.i3
Pages: 94
|
DOI: 10.1615/CritRevImmunol.v25.i3.30
|
Article price - $35.00 |
 |
Dendritic Cell-Derived Exosomes as Cell-Free Peptide-Based Vaccines
Julien Taieb
ERIT-M 02-08 INSERM, Department of Clinical Biology, Institut Gustave Roussy(IGR), 39 rue Camille Desmoulins, 94805 Villejuif; and Department of Hepatology and Gastroenterology, Pitie Salpetriere Hospital, Paris, France
Nathalie Chaput
ERIT-M 02-08 INSERM, Department of Clinical Biology, Institut Gustave Roussy(IGR), 39 rue Camille Desmoulins, 94805 Villejuif, France
Laurence Zitvogel
ERIT-M 02-08 INSERM, Department of Clinical Biology, Institut Gustave Roussy(IGR), 39 rue Camille Desmoulins, 94805 Villejuif, France
ABSTRACT
Dendritic cells (DC) are professional antigen-presenting cells and the only ones capable of inducing primary cytotoxic immune responses both in vivo and in vitro. DCs secrete a 60-100 nm membrane vesicle population of endocytic origin, called “exosomes.” The lipid and protein composition of DC-derived exosomes (DEX) is now well characterized. Besides MHC and costimulatory molecules, DEX bear several adhesion proteins, which are probably involved in their specific targeting. DEX also accumulate several cytosolic factors, most likely involved in exosome's biogenesis in late endosomes. In 1998, we reported that DEX are immunogenic in mice and lead to tumor rejection. These findings have renewed the interest in DEX. The current challenge consists of understanding the mechanisms and the physiological relevance of DEX, which could contribute to the design of the optimal DEX-based vaccination. In this review, we focus on the biological features of DEX and their immunostimulatory functions in mice and humans, and we discuss their potential clinical implementation in the immunotherapy of cancer.
pages 215-224
|
